-
Je něco špatně v tomto záznamu ?
Snižování koncentrací lipidů tyreoidálními hormony a tyreomimetiky
[Lipid lowering with thyroid hormone and thyromimetics]
Bo Angelin, Mats Rudling
Jazyk čeština Země Česko
Typ dokumentu přehledy
- MeSH
- ateroskleróza patofyziologie prevence a kontrola MeSH
- biomimetika metody MeSH
- financování organizované MeSH
- hormony štítné žlázy aplikace a dávkování chemická syntéza metabolismus terapeutické užití MeSH
- LDL-cholesterol metabolismus MeSH
- LDL-receptory agonisté metabolismus MeSH
- lidé MeSH
- metabolismus lipidů účinky léků MeSH
- molekulární mimikry fyziologie MeSH
- orgánová specificita MeSH
- statiny farmakologie MeSH
- štítná žláza fyziologie MeSH
- systém hypotalamus-hypofýza fyziologie MeSH
- tyreoidální hormony, receptory alfa agonisté metabolismus MeSH
- tyreoidální hormony, receptory beta agonisté metabolismus MeSH
- žlučové kyseliny a soli metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- přehledy MeSH
To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research. RECENT FINDINGS: Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRß is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TR? is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRß and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic-pituitary-thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a). SUMMARY: Liver-specific and ß-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.
Lipid lowering with thyroid hormone and thyromimetics
Lit.: 49
- 000
- 00000naa 2200000 a 4500
- 001
- bmc11011708
- 003
- CZ-PrNML
- 005
- 20111210211101.0
- 008
- 110525s2011 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Angelin, Bo $7 gn_A_00006888
- 245 10
- $a Snižování koncentrací lipidů tyreoidálními hormony a tyreomimetiky / $c Bo Angelin, Mats Rudling
- 246 11
- $a Lipid lowering with thyroid hormone and thyromimetics
- 314 __
- $a Metabolism Unit, Department of Endocrinology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. bo.angelin@ki.se
- 504 __
- $a Lit.: 49
- 520 9_
- $a To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research. RECENT FINDINGS: Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRß is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TR? is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRß and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic-pituitary-thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a). SUMMARY: Liver-specific and ß-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a ateroskleróza $x patofyziologie $x prevence a kontrola $7 D050197
- 650 _2
- $a žlučové kyseliny a soli $x metabolismus $7 D001647
- 650 _2
- $a biomimetika $x metody $7 D032701
- 650 _2
- $a LDL-cholesterol $x metabolismus $7 D008078
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x farmakologie $7 D019161
- 650 _2
- $a systém hypotalamus-hypofýza $x fyziologie $7 D007030
- 650 _2
- $a metabolismus lipidů $x účinky léků $7 D050356
- 650 _2
- $a molekulární mimikry $x fyziologie $7 D018716
- 650 _2
- $a orgánová specificita $7 D009928
- 650 _2
- $a LDL-receptory $x agonisté $x metabolismus $7 D011973
- 650 _2
- $a štítná žláza $x fyziologie $7 D013961
- 650 _2
- $a tyreoidální hormony, receptory alfa $x agonisté $x metabolismus $7 D037021
- 650 _2
- $a tyreoidální hormony, receptory beta $x agonisté $x metabolismus $7 D037042
- 650 _2
- $a hormony štítné žlázy $x aplikace a dávkování $x chemická syntéza $x metabolismus $x terapeutické užití $7 D013963
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Rudling, Mats
- 773 0_
- $w MED00156015 $t Current opinion in lipidology $g Roč. 5, č. 1 (2011), s. 16-22 $x 1802-372X
- 910 __
- $a ABA008 $b B 2483 $c 129 $y 2
- 990 __
- $a 20110525121334 $b ABA008
- 991 __
- $a 20110725105503 $b ABA008
- 999 __
- $a ok $b bmc $g 852832 $s 717797
- BAS __
- $a 3
- BMC __
- $a 2011 $b 5 $c 1 $d 16-22 $m Current Opinion in Lipidology $x MED00156015
- LZP __
- $a 2011-08/mkme